Exhibit 10.2 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Research Subaward Agreement Amendment Pass-Through Entity (PTE) Subrecipient Yale University Entity Name Miragen Therapeutics, Inc. Office of Sponsored Projects 25 Science Park, 3rd Floor 150 Munson Street, PO Box 208327 New Haven, CT 06520-8327 Address including City, State, Zip+4 (Country, if non-US) 6200 Lookout Road Boulder, CO 80301 [*], MD Principal Investigator Rusty Montgomery, MD PTE Federal Award No: Amendment No: Federal Awarding Agency: National Heart, Lung, and Blood Institute 5UH3HL123886-04 4 Project Title: Mir-29 mimicry as a therapy for pulmonary fibrosis Subaward Period of Performance: Amount Funded This Action: Subaward No: Start Date: Jul 1, 2017 End Date: Jun 30, 2018 $ [*] GR100301 (CON-80000904) Effective Date of Amendment: Total Amount of Federal Funds Obligated to Date: $ [*] Subject to FFATA: ✔ Yes No Jul 1, 2017 Amendment(s) to Original Terms and Conditions This Amendment revises the above-referenced Research Subaward Agreement as follows: Action: • Subaward Period of Performance extended to June 30, 2018. • Authorized Funding for Budget Period: [*] • Carry over is not automatic and requires prior approval. • Subaward No. revised to GR100301 (CON-80000904). Invoices that do not reference the revised Subaward No. will be returned to Subrecipient. Questions concerning invoices should be directed to Dennis Titley at dennis.titley@yale.edu. All other terms and conditions of this Subaward Agreement remain in full force and effect. By an Authorized Official of PTE: /s/ Andrea Lozano _ Name: Andrea Lozano Date 10/5 / 17 Title: Award Manager By an Authorized Official of Subrecipient: /s/ Jason Leverone 9/29/2017 | 10:18 AM MDT Name: Title: Jason Leverone Date Chief Financial Officer